corwave-pump-technology-45.html
Novo Annual Review 2016
46 / 71
selected portfolio company achievements in 2016 new pre-seed grants in 2016 antag
project
focuses
on the role of the gastric inhibitory polypeptide hormone in diabetes and obesity. childtreat
project
focuses
on the development of a novel treatment to prevent procedural pain in children. i sd-immunotech
project
focuses
on systemic lupus erythematosus (sle). sle is an autoimmune disease, characterised by systemic chronic inflammation. lox
project
focuses
on the tumour secreted lysyl oxidase, lox, that is closely correlated with cancer progression and metastasis. noncodania
project
focuses
on therapeutic application of non-protein coding rna molecules. reticare
focuses
on neuroprotection in eye disorders. tonsl
project
is developing a novel dna damage response (ddr) cancer therapy. glia
project
focuses
on the commercial aspects of pioneering cell therapy for central nerve system (cns) diseases. achievements in portfolio companies in 2016 galecto completed its first
clinical
phase iia study in idiopathic pulmonary fibrosis (ipf) patients. the galecto treatment was found to be effective and well tolerated. minervax has successfully concluded their phase ib study of the gbs vaccine. io biotech entered into a broad collaboration agreement with center for cancer immunotherpy (ccit) at herlev university hospital in copenhagen. through this collaboration, io biotech has gained access to several new
clinical
stage programmes, the first of which is a pd-l1 based vaccine, which is now being advanced to
clinical
proof of concept. acesion has obtained a new eur 4.2 million financial commitment from the wellcome trust. this occurred concurrently with the selection of a
clinical
candidate for further development. 46 novo a/s 2016
developing-company-www-47.html
